You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDroperidol
Accession NumberDB00450  (APRD00939)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)
Structure
Thumb
Synonyms
1-(1-(3-(P-Fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone
1-(1-(4-(P-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone
1-{1-[4-(4-fluoro-phenyl)-4-oxo-butyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1,3-dihydro-benzoimidazol-2-one
1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl}-2,3-dihydro-1H-benzo[D]imidazol-2-one
Droperidol
Dropéridol
Droperidolo
Droperidolum
External Identifiers
  • McN-JR 4749
  • R 4749
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Droperidol InjectionLiquid2.5 mgIntramuscular; IntravenousNovopharm Limited1998-04-202002-03-14Canada
Droperidol Injection USP 2.5mg/mlSolution2.5 mgIntramuscular; IntravenousSandoz Canada Incorporated1995-12-31Not applicableCanada
InapsineInjection2.5 mg/mLIntramuscular; IntravenousAkorn, Inc.1996-07-012016-11-15Us
InapsineInjection2.5 mg/mLIntramuscular; IntravenousAkorn, Inc.1996-07-012016-11-15Us
Inapsine Inj 2.5mg/mlLiquid2.5 mgIntramuscular; IntravenousJanssen Pharmaceutica, Division Of Janssen Ortho Inc.1982-12-311998-08-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DroperidolInjection, solution2.5 mg/mLIntramuscular; IntravenousHospira, Inc.1988-02-29Not applicableUs
DroperidolInjection, solution2.5 mg/mLIntramuscular; IntravenousAmerican Regent, Inc.1990-09-30Not applicableUs
DroperidolInjection, solution2.5 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2012-10-18Not applicableUs
DroperidolInjection, solution2.5 mg/mLIntramuscular; IntravenousCardinal Health1990-09-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DehydrobenzperidolJanssen
DridolProstrakan
DroleptanDaiichi Sankyo
DropedolExcelsior
DropelSiu Guan
DroperdalCristália
DroperidolsGrindeks
XomolixArzneimittel ProStrakan
Brand mixtures
NameLabellerIngredients
Innovar InjJanssen Pharmaceutica, Division Of Janssen Ortho Inc.
SaltsNot Available
Categories
UNIIO9U0F09D5X
CAS number548-73-2
WeightAverage: 379.4274
Monoisotopic: 379.169605168
Chemical FormulaC22H22FN3O2
InChI KeyRMEDXOLNCUSCGS-UHFFFAOYSA-N
InChI
InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)
IUPAC Name
1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
SMILES
FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=CC=CC=C12
Pharmacology
IndicationDroperidol is ssed to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.
Structured Indications
PharmacodynamicsDroperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of nausea and vomiting during surgical procedures and provides antiemetic protection in the postoperative period. Droperidol potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced arrhythmias, but it does not prevent other cardiac arrhythmias.
Mechanism of actionThe exact mechanism of action is unknown, however, droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation. It may antagonize the actions of glutamic acid within the extrapyramidal system. It may also inhibit cathecolamine receptors and the reuptake of neurotransmiters and has strong central antidopaminergic action and weak central anticholinergic action. It can also produce ganglionic blockade and reduced affective response. The main actions seem to stem from its potent Dopamine(2) receptor antagonism with minor antagonistic effects on alpha-1 adrenergic receptors as well.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
Alpha-1A adrenergic receptorProteinyes
antagonist
HumanP35348 details
Related Articles
AbsorptionCompletely absorbed following intramuscular administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Extensively metabolized.

Route of eliminationNot Available
Half lifeBiphasic distribution. The rapid distribution phase is 1.4 ± 0.5 minutes and the slower distribution phase is 14.3 ± 6.5 minutes. Elimination half-life in adults is 134 ± 13 minutes and may be increased in geriatric patients. In children, it is 101.5 ± 26.4 minutes.
ClearanceNot Available
ToxicityThe intravenous LD50 of droperidol is 20-43 mg/kg in mice; 30 mg/kg in rats; 25 mg/kg in dogs and 11-13 mg/kg in rabbits. The intramuscular LD50 of droperidol is 195 mg/kg in mice, 104-110 mg/kg in rats; 97 mg/kg in rabbits and 200 mg/kg in guinea pigs. The manifestations of droperidol overdosage are an extension of its pharmacologic actions.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneDroperidol may increase the central nervous system depressant (CNS depressant) activities of 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineDroperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineDroperidol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineDroperidol may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineDroperidol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleDroperidol may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Experimental
AcepromazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Vet Approved
AceprometazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
adipiplonDroperidol may increase the central nervous system depressant (CNS depressant) activities of adipiplon.Investigational
AgomelatineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Investigational
AlfaxaloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Vet Approved
AlfentanilDroperidol may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Droperidol.Approved, Investigational
AlphacetylmethadolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.Experimental, Illicit
AlprazolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Droperidol can be decreased when used in combination with Amantadine.Approved
AmiodaroneDroperidol may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Droperidol is combined with Amisulpride.Approved, Investigational
AmitriptylineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
AmobarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Illicit
AmoxapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
AmperozideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Experimental
AmphetamineDroperidol may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AnagrelideDroperidol may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineThe therapeutic efficacy of Droperidol can be decreased when used in combination with Apomorphine.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
AripiprazoleDroperidol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
Arsenic trioxideDroperidol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherDroperidol may increase the QTc-prolonging activities of Artemether.Approved
ArticaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
AsenapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
AtazanavirAtazanavir may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Droperidol.Approved
AzaperoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Vet Approved
AzelastineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Droperidol.Approved
BaclofenDroperidol may increase the central nervous system depressant (CNS depressant) activities of Baclofen.Approved
BarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Barbital.Illicit
BedaquilineDroperidol may increase the QTc-prolonging activities of Bedaquiline.Approved
BenperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Benperidol.Investigational
BenzocaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved
BenzphetamineDroperidol may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholDroperidol may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
BrexpiprazoleDroperidol may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved
BrimonidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
BromazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Illicit
BromocriptineThe therapeutic efficacy of Droperidol can be decreased when used in combination with Bromocriptine.Approved, Investigational
BrompheniramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
BrotizolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.Approved, Withdrawn
BupivacaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Investigational
BuprenorphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Droperidol.Approved
BuspironeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
ButabarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Illicit
ButacaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butacaine.Vet Approved
ButalbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Illicit
ButambenDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved
ButethalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butethal.Approved, Illicit
ButorphanolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Droperidol.Approved
CarbamazepineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
CarbinoxamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
CarfentanilDroperidol may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.Illicit, Vet Approved
CarisoprodolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
CeritinibDroperidol may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
Chloral hydrateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.Approved, Illicit
ChlormezanoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.Approved, Withdrawn
ChloroprocaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
ChloroquineDroperidol may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
ChlorphentermineDroperidol may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
CinchocaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Vet Approved
CiprofloxacinDroperidol may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideDroperidol may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramDroperidol may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinDroperidol may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clemastine.Approved
ClidiniumDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
ClobazamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clobazam.Approved, Illicit
clomethiazoleDroperidol may increase the central nervous system depressant (CNS depressant) activities of clomethiazole.Investigational
ClomipramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Vet Approved
ClonazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Illicit
ClonidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
ClorazepateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Illicit
ClozapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
CocaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cocaine.Approved, Illicit
CodeineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Illicit
CrizotinibDroperidol may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.Approved
CyclobenzaprineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
CyproheptadineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
DabrafenibDabrafenib may increase the QTc-prolonging activities of Droperidol.Approved
DantroleneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
DapiprazoleDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Droperidol is combined with Dapoxetine.Investigational
DasatinibDasatinib may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Droperidol.Approved
deramciclaneDroperidol may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Investigational
DesfluraneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
DesipramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved
DesloratadineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Droperidol.Approved
DetomidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Detomidine.Vet Approved
DexbrompheniramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
DexmedetomidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDroperidol may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Droperidol.Approved
DextromoramideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dezocine.Approved
DiazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Diazepam.Approved, Illicit, Vet Approved
DiethylpropionDroperidol may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.Approved, Illicit
DihydrocodeineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Droperidol.Approved
DihydroetorphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
DiphenhydramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved
DiphenoxylateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Illicit
DisopyramideDroperidol may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideDroperidol may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronDroperidol may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneDroperidol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Doramectin.Vet Approved
DoxepinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved
DoxylamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved, Vet Approved
DPDPEDroperidol may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Droperidol.Approved, Illicit
DronedaroneDroperidol may increase the QTc-prolonging activities of Dronedarone.Approved
DrotebanolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Droperidol.Approved
DyclonineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
EcgonineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERDroperidol may increase the central nervous system depressant (CNS depressant) activities of ECGONINE METHYL ESTER.Experimental
EcopipamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Investigational
EfavirenzDroperidol may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Droperidol.Approved, Investigational
EliglustatDroperidol may increase the QTc-prolonging activities of Eliglustat.Approved
EnfluraneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Enflurane.Approved, Vet Approved
EntacaponeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Droperidol.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Droperidol.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Droperidol.Approved
EribulinEribulin may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
EscitalopramDroperidol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstazolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Estazolam.Approved, Illicit
EszopicloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved
EthanolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
EthotoinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
Ethyl carbamateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Withdrawn
Ethyl loflazepateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Illicit
EthylmorphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Illicit
EtidocaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.Approved
EtifoxineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.Withdrawn
EtizolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Etizolam.Approved
EtomidateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Etoperidone.Approved
EtorphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Etorphine.Illicit, Vet Approved
EzogabineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Droperidol.Approved
FelbamateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
FencamfamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Illicit, Withdrawn
FentanylDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
FlecainideDroperidol may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Droperidol.Approved
FludiazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Illicit
FlunarizineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
FlunitrazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.Approved, Illicit
FluoxetineDroperidol may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Withdrawn
FluphenazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
FlurazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Illicit
FluspirileneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved
Fluticasone PropionateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluticasone Propionate.Approved
FluvoxamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Droperidol.Approved
FosphenytoinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.Approved
FospropofolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Droperidol.Approved, Investigational
GabapentinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
gabapentin enacarbilDroperidol may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved
Gadobenic acidDroperidol may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Droperidol.Approved
Gamma Hydroxybutyric AcidDroperidol may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.Approved, Illicit
GemifloxacinDroperidol may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Gepirone.Investigational
GlutethimideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.Approved, Illicit
GoserelinGoserelin may increase the QTc-prolonging activities of Droperidol.Approved
GranisetronDroperidol may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Investigational
HalazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Halazepam.Approved, Illicit, Withdrawn
HaloperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
HalothaneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Vet Approved
HeroinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Heroin.Approved, Illicit
HexobarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Droperidol.Approved
HydrocodoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideDroperidol may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hydroxyzine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
IbutilideDroperidol may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
ImipramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Droperidol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Droperidol is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Droperidol.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Droperidol.Approved
IsofluraneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.Approved, Vet Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Droperidol.Approved
ItraconazoleItraconazole may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Droperidol.Approved
KetamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
KetazolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
KetobemidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
LamotrigineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
LenvatinibDroperidol may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
LevetiracetamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
LevobupivacaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.Approved
LevocabastineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.Approved
LevocetirizineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
LevodopaDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved
LevofloxacinDroperidol may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Droperidol.Approved
LevorphanolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
LidocaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Droperidol.Approved, Investigational
LisdexamfetamineDroperidol may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
LofentanilDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.Illicit
LopinavirDroperidol may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved
LorazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Droperidol.Approved
LoxapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
Lu AA21004Droperidol may increase the central nervous system depressant (CNS depressant) activities of Lu AA21004.Investigational
LumefantrineDroperidol may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
Magnesium SulfateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved, Vet Approved
MaprotilineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
MeclizineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
MedetomidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Droperidol.Approved
MelatoninDroperidol may increase the central nervous system depressant (CNS depressant) activities of Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Melperone.Approved
MephedroneDroperidol may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineDroperidol may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
MeprobamateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Illicit
MequitazineDroperidol may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved
MetaxaloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
MethadoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate.Approved, Illicit
MethamphetamineDroperidol may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Withdrawn
MethaqualoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.Illicit, Withdrawn
MethocarbamolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
MethohexitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
MethotrimeprazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Vet Approved
MethsuximideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Droperidol is combined with Metoclopramide.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Droperidol.Approved
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Droperidol.Approved
MidazolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Droperidol.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Droperidol.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Droperidol.Approved
MirtazapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDADroperidol may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Droperidol.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Droperidol.Approved
MolindoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
MorphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
NabiloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved, Investigational
NalbuphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Droperidol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Droperidol.Approved, Withdrawn
NelfinavirNelfinavir may increase the QTc-prolonging activities of Droperidol.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Droperidol.Approved
NilotinibDroperidol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
Nitrous oxideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.Approved, Vet Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Droperidol.Approved
NormethadoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Normethadone.Approved, Illicit
NortriptylineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
OfloxacinDroperidol may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Droperidol.Approved
OlopatadineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
OndansetronDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
OpiumDroperidol may increase the central nervous system depressant (CNS depressant) activities of Opium.Approved, Illicit
OrphenadrineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantDroperidol may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Investigational
OxazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
OxetacaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxetacaine.Investigational
OxprenololDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved
OxybuprocaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.Approved
OxycodoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
PaliperidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
PanobinostatDroperidol may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParaldehydeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Droperidol.Approved
PazopanibDroperidol may increase the QTc-prolonging activities of Pazopanib.Approved
PentamidineDroperidol may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
PentobarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Vet Approved
PerampanelDroperidol may increase the central nervous system depressant (CNS depressant) activities of Perampanel.Approved
PerazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Perazine.Investigational
PerflutrenDroperidol may increase the QTc-prolonging activities of Perflutren.Approved
PerospironeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
PerphenazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
PethidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Droperidol.Approved
PhenobarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved
PhenoxyethanolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.Approved
PhentermineDroperidol may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.Approved, Vet Approved
PimozideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
PipamperoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved
PipotiazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Droperidol can be decreased when used in combination with Piribedil.Investigational
PiritramideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Piritramide.Investigational
PizotifenDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.Approved
PomalidomideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Droperidol.Approved, Investigational, Vet Approved
PramipexoleDroperidol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
PrazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Illicit
PregabalinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Illicit, Investigational
PregnanoloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pregnanolone.Investigational
PrilocaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.Approved
PrimaquineDroperidol may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Primidone.Approved, Vet Approved
ProcainamideDroperidol may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Droperidol.Approved
ProchlorperazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
PromazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
PromethazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved
PropafenoneDroperidol may increase the QTc-prolonging activities of Propafenone.Approved
ProparacaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Vet Approved
PropofolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational, Vet Approved
PropoxycaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.Approved
ProtriptylineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
PSD502Droperidol may increase the central nervous system depressant (CNS depressant) activities of PSD502.Investigational
PseudoephedrineDroperidol may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Illicit
QuetiapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Droperidol.Approved
QuinidineDroperidol may increase the QTc-prolonging activities of Quinidine.Approved
QuinineDroperidol may increase the QTc-prolonging activities of Quinine.Approved
RacloprideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Raclopride.Investigational
RamelteonDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Investigational
RanolazineRanolazine may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Droperidol.Approved
RemifentanilDroperidol may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
RemoxiprideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Withdrawn
ReserpineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Droperidol.Approved
RisperidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Investigational
RitanserinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ritanserin.Investigational
RitobegronDroperidol may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Droperidol.Approved
RomifidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Romifidine.Vet Approved
RopiniroleDroperidol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
RotigotineDroperidol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Droperidol.Approved
S-EthylisothioureaDroperidol may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Experimental
Sage 547Droperidol may increase the central nervous system depressant (CNS depressant) activities of Sage 547.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Droperidol.Approved
SaquinavirDroperidol may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ScopolamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
SecobarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Droperidol.Approved, Investigational, Vet Approved
SertindoleDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Droperidol.Approved
SevofluraneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
Sodium oxybateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Droperidol.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
SotalolDroperidol may increase the QTc-prolonging activities of Sotalol.Approved
StiripentolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.Approved
SufentanilDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Droperidol.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Droperidol is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Droperidol.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
SuvorexantDroperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenTamoxifen may increase the QTc-prolonging activities of Droperidol.Approved
TandospironeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tandospirone.Investigational
TapentadolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.Approved
TasimelteonDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Droperidol.Approved
TelavancinDroperidol may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinDroperidol may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Droperidol.Approved
TetrabenazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved
TetracaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Vet Approved
TetrodotoxinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Investigational
ThalidomideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
ThiopentalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Vet Approved
ThioridazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved
ThiothixeneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
TiagabineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved
TiaprideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Investigational
TiletamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.Vet Approved
TizanidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved
TolcaponeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
TopiramateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
ToremifeneDroperidol may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
TrazodoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
TriazolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved
TrifluoperazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
TriflupromazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
TrimipramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
TriprolidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
Uc1010Droperidol may increase the central nervous system depressant (CNS depressant) activities of Uc1010.Investigational
Valproic AcidDroperidol may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.Approved, Investigational
VandetanibDroperidol may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Droperidol.Approved
VemurafenibDroperidol may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Droperidol.Approved
VigabatrinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Droperidol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Droperidol.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
VortioxetineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
XylazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Xylazine.Vet Approved
ZaleplonDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Illicit, Investigational
ZiconotideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Droperidol is combined with Zimelidine.Withdrawn
ZiprasidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
ZolazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Droperidol.Approved, Investigational
ZolpidemDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
ZopicloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.Approved
ZotepineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zotepine.Approved
ZuclopenthixolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Janssen, P.A.J. and Gardocki, J.F.; U.S. Patent 3,141,823; July 21, 1964; assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.
Januen, P.A.J.; U.S. Patent 3,161,645; December 15,1964: assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.

US3161645
General ReferencesNot Available
External Links
ATC CodesN05AD08
AHFS Codes
  • 28:24.92
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9602
Caco-2 permeable-0.7521
P-glycoprotein substrateSubstrate0.7471
P-glycoprotein inhibitor IInhibitor0.9128
P-glycoprotein inhibitor IIInhibitor0.7451
Renal organic cation transporterInhibitor0.67
CYP450 2C9 substrateNon-substrate0.7884
CYP450 2D6 substrateNon-substrate0.8756
CYP450 3A4 substrateSubstrate0.6751
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9279
Ames testNon AMES toxic0.6353
CarcinogenicityNon-carcinogens0.9104
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5820 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8955
hERG inhibition (predictor II)Inhibitor0.835
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abraxis pharmaceutical products
  • Astrazeneca lp
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Smith and nephew solopak div smith and nephew
  • Solopak laboratories inc
  • Watson laboratories inc
  • Akorn inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular; Intravenous2.5 mg/mL
SolutionIntramuscular; Intravenous2.5 mg
InjectionIntramuscular; Intravenous2.5 mg/mL
LiquidIntramuscular; Intravenous2.5 mg
LiquidIntramuscular; Intravenous
Prices
Unit descriptionCostUnit
Inapsine 2.5 mg/ml ampul4.59USD ml
Droperidol 2.5 mg/ml vial2.04USD ml
Droperidol 2.5 mg/ml ampul0.7USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point145-146.5Janssen, P.A.J. and Gardocki, J.F.; U.S. Patent 3,141,823; July 21, 1964; assigned to Research Laboratorium Dr. C. Janssen NV, Belgium. Januen, P.A.J.; U.S. Patent 3,161,645; December 15,1964: assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.
water solubility4.21 mg/LNot Available
logP3.50SANGSTER (1993)
pKa7.46SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0966 mg/mLALOGPS
logP3.93ALOGPS
logP3.01ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)12.72ChemAxon
pKa (Strongest Basic)6.75ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.65 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity109.52 m3·mol-1ChemAxon
Polarizability40.31 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylbutylamines
Direct ParentPhenylbutylamines
Alternative Parents
Substituents
  • Phenylbutylamine
  • Butyrophenone
  • Benzimidazole
  • Acetophenone
  • Aryl alkyl ketone
  • Aryl ketone
  • Benzoyl
  • Tetrahydropyridine
  • N-substituted imidazole
  • Hydropyridine
  • Gamma-aminoketone
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Urea
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Grip G, Svensson BA, Gordh T Jr, Post C, Hartvig P: Histopathology and evaluation of potentiation of morphine-induced antinociception by intrathecal droperidol in the rat. Acta Anaesthesiol Scand. 1992 Feb;36(2):145-52. [PubMed:1549935 ]
  2. Hamik A, Peroutka SJ: Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors. Cancer Chemother Pharmacol. 1989;24(5):307-10. [PubMed:2527092 ]
  3. Larson MD: The effect of antiemetics on pupillary reflex dilation during epidural/general anesthesia. Anesth Analg. 2003 Dec;97(6):1652-6. [PubMed:14633536 ]
  4. Gao HR, Shi TF, Yang CX, Zhang D, Zhang GW, Zhang Y, Jiao RS, Zhang H, Xu MY: The effect of dopamine on pain-related neurons in the parafascicular nucleus of rats. J Neural Transm (Vienna). 2010 May;117(5):585-91. doi: 10.1007/s00702-010-0398-3. Epub 2010 Apr 1. [PubMed:20358234 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Zupko I, Janossy K, Maul K, Marki A, Falkay G: Alpha-adrenergic blockade: a possible mechanism of tocolytic action of certain benzodiazepines in a postpartum rat model in vivo. Life Sci. 2003 Jan 24;72(10):1093-102. [PubMed:12505540 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23